Avadel Pharmaceuticals — Flamel Technologies — Investor Presentation (May 2016)
30 slides from Avadel Pharmaceuticals's investor presentation, May 4, 2016
Slide 1: May 2016 1
May 2016 1
Slide 2: Forward Looking Statements
May 2016 2 Forward Looking Statements This presentation may include "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements herein that are not clearly historical in nature are forward - looking, and the words "anticipate," "assume,"
Slide 3: Investment Highlights
May 2016 3 Investment Highlights • Strong financial position – profitable with strong cash flow & balance sheet ▪ $173.2 million in product revenues in 2015 ▪ $ 84.3 million cash flow from operations generated in 2015; no debt • Initiating Phase III pivotal trial using Micropump ® sodium oxybate in
Slide 4: Flamel Technologies Transformed
May 2016 4 Flamel Technologies Transformed Est. as a drug delivery & formulation company 1990 2007 Coreg CR® using Micropump ® receives FDA approval (GSK partnered product) 2012 Flamel acquires Éclat Pharmaceuticals 2013 FDA approval for Bloxiverz ® 2014 FDA approval for Vazculep ® M anufacturing fa
Slide 5: 2016 Expectations
May 2016 5 2016 Expectations • Commence patient registration & dosing for pivotal study of Micropump ® sodium oxybate by mid year • Complete cross border merger to Ireland • Launch Akovaz ™ (Approved on April 29, 2016) • Integrate & market newly acquired FSC Pediatrics’ products • Begin licensing di
Slide 6: Current Pipeline
May 2016 6 Drug/ Technology Indication Proof of Concept Pilot Pivotal Under Review Approved UMD # 4 Undisclosed Sodium oxybate/ Micropump® Narcolepsy Ibuprofen / LiquiTime® Pain / Fever Guaifenesin / LiquiTime® Respiratory Hydromorphone / Trigger Lock™ Pain Exenatide/Medusa™ Diabetes Current Pipelin
Slide 7: Micropump Sodium Oxybate (FT218) Overview
May 2016 7 FT218 Overview • Extended release oral solid formulation of sodium oxybate using Micropump ® • Studied in 40 healthy volunteers across 2 studies • Standard of care: Jazz’s Xyrem ® dosed 2x nightly ▪ Improved formulation needed: Micropump ® profile consistent with target of 1x dose before
Slide 8: Trigger Lock Hydromorphone (FT227) Overview
May 2016 8 FT227 Overview • Abuse - deterrent, extended - release, oral hydromorphone product for treatment of pain – technology is applicable to all opioids • Positive results from two pilot PK studies in healthy volunteers announced in June 2015 • Next step : Continue dialogue with FDA regarding p
Slide 9: Medusa Exenatide (FT228) Overview
May 2016 9 FT228 Overview • Subcutaneous injection formulation of exenatide , a GLP - 1 (glucagon - like peptide – 1 ) for treatment of Type 2 diabetes • Interim Phase I human clinical data reported in December 2015 • PK profile compatible with a release over one week in humans • Next step : Complet
Slide 10: LiquiTime Platform Overview
May 2016 10 Overview • Extended release liquid oral suspension for more convenient and improved dosing with a focus on pediatric and geriatric markets • Exclusive U . S . rights licensed to Perrigo for the OTC drug market : development ongoing • Flexible capability allows for the combination of mult
Slide 11: Marketed Products
May 2016 11 Marketed Products
Slide 12: Éclat Portfolio Products
May 2016 12 Éclat Portfolio Products * IMS data Bloxiverz ® (neostigmine methylsulfate injection) • Indication: Reverses neuromuscular blockades used in surgical procedures • 1 of 3 approved versions; ~ 4 million vials sold annually in the U.S. * Vazculep ® (phenylephrine hydrochloride injection) •
Slide 13: FSC Acquisition
May 2016 13 FSC Acquisition • Commercial stage specialty pharmaceuticals company headquartered Charlotte, NC • Provides 4 commercial stage assets to be marketed by 45 person salesforce • Positions Flamel as a more attractive business partner for potential pediatric and geriatric assets • Fixed acqui
Slide 14: FSC Products
May 2016 14 FSC Products • Indication: Perennial allergic rhinitis in children 2 years of age and older • Patent protection through March 2029 • Rx antihistamine market size in U.S. ~ $11M • Indication: 2nd generation Cephalosporin covering a variety of common pathogens • For children as young as 1
Slide 15: Strong Intellectual Property Platform
May 2016 15 Strong Intellectual Property Platform US Europe Micropump® July 2027 July 2023 LiquiTime® September 2025 April 2023 Trigger Lock™ April 2027 May 2026 (pending) Medusa™ June 2031 June 2027 (pending) Product US Karbinal ™ ER March 2029 AcipHex ® Sprinkle™ September 2016 Flexichamber ® Marc
Slide 16: Seasoned Senior Management
May 2016 16 Seasoned Senior Management Name Title Experience Michael S. Anderson Chief Executive Officer 40+ years Pharma Sandy Hatten Senior Vice President, Quality and Regulatory Affairs 30+ years Pharma Phillandas T. Thompson, J.D., M.B.A. Senior Vice President, General Counsel 16+ years Legal Mi
Slide 17: Key Financial Metrics (Unaudited)
May 2016 17 Key Financial Metrics (Unaudited) Income Statement Metrics Twelve months ended December 31, 2015 2014 Revenue $ 173.2 $14.8 COGS (10.9) (3.4) R&D (25.6) (17.3) SG&A (21.7) (15.7) Acquisition Earn - Out Payments/Accruals (32.2) (1.7) Adj Op. Profit (Loss) * 82.8 (23.3) Adj. Net Income (Lo
Slide 18: Flamel Technologies Transformed
May 2016 18 Flamel Technologies Transformed • Strong financial condition - profitable with strong cash flow and balance sheet • Seven FDA approved products • Experienced management team • Robust pipeline with extensive IP protection Mission: To build a diversified specialty pharmaceutical company th
Slide 19: Appendix
FLAMEL Appendix May 2016 f
Slide 20: Reconciliation of Non GAAP to GAAP Results
May 2016 20 Reconciliation of Non GAAP to GAAP Results
Slide 21: Diversified and Proven Drug Delivery Platforms
May 2016 21 Diversified and Proven Drug Delivery Platforms • Outstanding drug delivery platforms to tackle key challenges in the formulation, in various dosage forms (e . g . capsules, tablets, sachets or oral liquid suspensions ; or injectable for subcutaneous administration) of a broad range of dr
Slide 22: Micropump Platform at a Glance
May 2016 22 Micropump® Platform a t a Glance • Extended/delayed - release of drugs in the GI tract • Precise pharmacokinetics of single or combination of drugs in various formats • Numerous Micropump® - based products successfully tested in human clinical trials Various dosage forms (tablet, capsule
Slide 23: Micropump Microparticles for Controlled/Modified Release
May 2016 23 • Microparticles are dispersed in the stomach and pass into the small intestine, after which each microparticle releases the drug at an adjustable rate and over an extended period of time (up to 24 hours) • Drug released at an adjustable rate controlled and/or delayed • Micropump® microp
Slide 24: LiquiTime Platform at a Glance
May 2016 24 LiquiTime® Platform at a Glance LiquiTime® is a novel, proprietary and innovative delivery platform allowing the stable L iquid and controlled release formulation of one or several combined drugs over Time LiquiTime® meets challenges faced in the treatment of pediatric and geriatric pati
Slide 25: LiquiTime for Extended-Release Liquid Suspension
May 2016 25 Each microparticle is individually coated and behaves as an independent micro reservoir Coating • controls diffusion • keeps its integrity • offers good resistance to stress LiquiTime® f or Extended - Release Liquid Suspension L iquid suspension contains small coated drug microparticles
Slide 26: Trigger Lock Platform at a Glance
May 2016 26 Trigger Lock™ is a proprietary and innovative delivery platform that enables the controlled release of narcotic and opioid analgesics while deterring their abuse Trigger Lock™ successfully addresses the issues of narcotic/opioid analgesics tampering : x The sustained release Micropump® -
Slide 27: Trigger Lock SR Microparticles for Abuse Resistance
May 2016 27 1. Drug loaded Micropump® microparticles Sustained Release (SR) microparticles which are resistant to crushing 2. Viscosifying ingredient(s) To prevent abuse by injection after extraction in a small volume of solvent 3. Quenching ingredient(s) To prevent extraction in large volumes of li
Slide 28: Medusa Platform at a Glance
May 2016 28 Medusa Depot Solubilization and stabilization of drugs Applicable to a wide range of small molecules, peptide and protein drugs Safe, non - immunogenic and fully biodegradable Sustained delivery from 1 to 7 days in human Combination of several different drugs in the same formulation Bio
Slide 29: Medusa Depot for Injection
May 2016 29 Medusa ™ Depot for Injection COO - Na + COO - Na + COO - Na + COO - Na + COO - Na + COO - Na + COO - Na + Vitamin E Polyglutamate chain Drug solution or powder Formulation by simple mixing in water Non - covalent association ( reversible hydrophobic and/or electrostatic interaction) of t
Slide 30: Headquarters and Contact
May 2016 30 Headquarters 33 avenue du Dr . Georges Levy 69200 Vénissieux (Lyon) France U . S . Commercial Operations 16640 Chesterfield Grove Road, Suite 200 Chesterfield, MO Corporate Contact Phone : + 33 472 783 434 Fax : + 33 472 783 435 E - mail : licensing@flamel . com Specialty Pharmaceutical
Flamel Technologies — Investor Presentation (May 2016) on 6ix